The pan-JAK inhibitor delgocitinib in a cream formulation demonstrates dose response in chronic hand eczema in a 16-week randomized phase IIb trial

Autor: Margitta Worm, Jacob P. Thyssen, Sibylle Schliemann, Andrea Bauer, Vivian Y. Shi, Ben Ehst, Sandra Tillmann, Sofie Korn, Katarina Resen, Tove Agner

Publikováno v: Worm, M, Thyssen, J P, Schliemann, S, Bauer, A, Shi, V Y, Ehst, B, Tillmann, S, Korn, S, Resen, K & Agner, T 2022, ' The pan-JAK inhibitor delgocitinib in a cream formulation demonstrates dose response in chronic hand eczema in a 16-week randomized phase IIb trial ', British Journal of Dermatology, vol. 187, no. 1, pp. 42-51 . https://doi.org/10.1111/bjd.21037

Background: Chronic hand eczema (CHE) is a burdensome disease, and new well-documented, safe and efficacious treatments are warranted. In a recent CHE phase IIa trial, the pan-Janus kinase (JAK) inhibitor delgocitinib in an ointment formulation was f

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d8bbc00f1dd0f45ae07c5c9910cc329
https://curis.ku.dk/portal/da/publications/the-panjak-inhibitor-delgocitinib-in-a-cream-formulation-demonstrates-dose-response-in-chronic-hand-eczema-in-a-16week-randomized-phase-iib-trial(7c0271af-7803-4981-9820-a1ab75ccbce2).html

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.